

Jun 16, 2008

NuPathe Inc. CEO to Present at the Leerink Swann Emerging Technologies in Pain Medicine Conference, New York City, Monday, June 23, 2008, Sofitel New York

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--NuPathe Inc., a privately held specialty pharmaceutical company developing innovative products for the treatment of neurological and psychiatric diseases, today announced that Jane Hollingsworth, chief executive officer, will present at the Leerink Swann Emerging Technologies in Pain Conference at 2:00pm on June 23, 2008 at the Sofitel, New York Hotel located at 45 West 44th Street in NYC.

Ms. Hollingsworth's presentation will focus on NP101, a novel transdermal patch in clinical development for the treatment of acute migraine. NP101, NuPathe's lead product, is currently being evaluated in Phase III clinical trials. She will also discuss NP201, a long-acting formulation of a dopamine agonist for Parkinson's disease. The company's products are based on reformulations of approved pharmaceuticals using NuPathe's proprietary delivery technologies, SmartRelief™ and LAD™. Combining these technologies with known molecules can provide significant clinical advantages over existing therapeutic options.

Mark Pierce, M.D., Ph.D., chief scientific officer for NuPathe, will serve on a distinguished panel of company representatives from 2:40pm – 3:40pm that day. The panel will address "The Best Offense is a Good Defense: Novel Ways of Tackling Pain."

About NuPathe

NuPathe Inc. is a specialty pharmaceutical company developing innovative therapeutic products for the treatment of neurological and psychiatric diseases. NuPathe's mission is to identify and address the needs of patients that are insufficiently met by current treatments. NuPathe's product portfolio includes NP101, which, if approved, will be the first and only transdermal patch for the treatment of acute migraine, and NP201, an injectable implant for the long-term management of Parkinson's disease.

About NP101

NP101 is a transdermal treatment in clinical development for acute migraine. Today, only 50% of migraine patients are satisfied with their migraine treatment due to issues such as migraine-associated nausea/vomiting, inconsistent relief, and side-effects. NP101 was designed to address these issues, providing patients with improved ability to take control over their migraine as compared to currently available oral and non-oral options.

NP101 is based on NuPathe's proprietary SmartRelief™ technology, a breakthrough in iontophoretic patch technology that utilizes low-level electrical energy to transport drugs through the skin.

Media Contact:

Ron Schmid
NuPathe – Vice President – Communications and Investor Relations
227 Washington Street
Conshohocken, PA 19428
Tel: 484-567-0130 ext. 1109
Cell: 610-659-3985